Annexon's neurological disease drug meets main goal of late-stage study (updated)

Annexon

04/06/2024 12:25

(Adds share movement in paragraph 1, details in paragraphs 2-4)
       June 4 (Reuters) - Annexon  ANNX.O  said on Tuesday its
experimental drug to treat a rare neurological disease met the
main goal of a late-stage trial, sending its shares up more than
31% before the bell.
    The trial was testing the drug, ANX005, in 241 patients with
the Guillain-Barre syndrome, a neurological disease in which the
body's immune system attacks the nerves causing muscle weakness.
    The company said the drug achieved a highly statistically
significant 2.4-fold improvement on a disability scale that
measures motor functions at eight weeks.
    The drug also showed improvements versus a placebo on key
secondary endpoints, Annexon said.

 (Reporting by Sneha  S K; Editing by Shilpi Majumdar)
 ((Sneha.SK@thomsonreuters.com;))